<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797159</url>
  </required_header>
  <id_info>
    <org_study_id>J12127</org_study_id>
    <secondary_id>NA_00078659</secondary_id>
    <nct_id>NCT01797159</nct_id>
  </id_info>
  <brief_title>Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer</brief_title>
  <official_title>&quot;A Phase II Trial of Hippocampal-Sparing Cranial Irradiation (PCI) for Small-Cell Lung Cancer (SCLC)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators are looking to compare standard treatment for the management of small cell&#xD;
      lung cancer (SCLC) which is prophylactic cranial Irradiation (PCI) (shown to be very good in&#xD;
      patient survival) with cranial sparing PCI. Although standard of care PCI is successful in&#xD;
      patient survival it also has neurologic side-effects. The Investigators are hoping the&#xD;
      cranial sparing PCI has the same positive survival results with the added benefit of lowering&#xD;
      neurological side-effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard of care in management of small cell lung cancer consists of chemotherapy plus&#xD;
      thoracic radiation followed by prophylactic cranial irradiation (PCI) based on a randomized&#xD;
      trial that demonstrated a significant improvement in overall survival (OS) with PCI.&#xD;
      Unfortunately radiation therapy to the brain is associated with neurocognitive toxicity,&#xD;
      which may be at least in part related to radiation induced injury to neural progenitor cells&#xD;
      in the hippocampus. Both human and animal data suggest an inverse relationship between&#xD;
      radiation dose to the hippocampus and performance on neuropsychological testing. We&#xD;
      hypothesize that hippocampal sparing PCI will allow improved performance on tests of short&#xD;
      term memory and executive function compared to a historical control (RTOG 0212) receiving the&#xD;
      same dose of conventional PCI. The primary objective of this study is to evaluate performance&#xD;
      on the Hopkins Verbal Learning Test-Revised for delayed recall at 6 months following&#xD;
      hippocampal-sparing PCI relative to the historical control. Secondary objectives are to&#xD;
      estimate: 1) composite cognitive function following hippocampal-sparing PCI relative to the&#xD;
      historical control and 2) the rate of metastases in the hippocampus at 2 years following&#xD;
      hippocampal-sparing PCI. The long term goal of this research is to reduce the long term&#xD;
      sequelae of radiation therapy for both primary and metastatic brain tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2013</start_date>
  <completion_date type="Actual">March 18, 2019</completion_date>
  <primary_completion_date type="Actual">March 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) on Possible Delayed Recall Toxicity as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R) for Delayed Recall</measure>
    <time_frame>Baseline, 6 months and 12 months post radiation treatment</time_frame>
    <description>The primary endpoint of this study is cognitive function or memory. Memory is measured by participant performance on the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-Delayed Recall) at 6 months following hippocampal-sparing PCI. The HVLT-Delayed minimum and Maximum scores are 0-12. A higher score means a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</measure>
    <time_frame>Baseline</time_frame>
    <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</measure>
    <time_frame>6 months post radiation treatment</time_frame>
    <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</measure>
    <time_frame>12 months post radiation treatment</time_frame>
    <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire (QLQ)-C30</measure>
    <time_frame>Baseline and 6 months post radiation treatment</time_frame>
    <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from &quot;not at all&quot; to &quot;very much&quot;. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following:&#xD;
Dyspnoea&#xD;
Insomnia&#xD;
Appetite&#xD;
Constipation&#xD;
Diarrhoea&#xD;
Finances&#xD;
Fatigue&#xD;
Nausea/Vomiting&#xD;
Pain&#xD;
Physical Function&#xD;
Role Function&#xD;
Emotional Function&#xD;
Cognitive Function&#xD;
Social Function&#xD;
Global QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment QLQ-C30</measure>
    <time_frame>Baseline and 12 months post radiation treatment</time_frame>
    <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from &quot;not at all&quot; to &quot;very much&quot;. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following:&#xD;
Dyspnoea&#xD;
Insomnia&#xD;
Appetite&#xD;
Constipation&#xD;
Diarrhoea&#xD;
Finances&#xD;
Fatigue&#xD;
Nausea/Vomiting&#xD;
Pain&#xD;
Physical Function&#xD;
Role Function&#xD;
Emotional Function&#xD;
Cognitive Function&#xD;
Social Function&#xD;
Global QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire-Brain Cancer (QLQ-BN20)</measure>
    <time_frame>Baseline and 6 months post radiation treatment</time_frame>
    <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following:&#xD;
Headaches&#xD;
Seizures&#xD;
Drowsy&#xD;
Hair loss&#xD;
Itching&#xD;
Weakness&#xD;
Bladder&#xD;
Future Uncertainty&#xD;
Visual Disorder&#xD;
Motor Dysfunction&#xD;
Communication Deficit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Using the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20).</measure>
    <time_frame>Baseline and 12 months post radiation treatment</time_frame>
    <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following:&#xD;
Headaches&#xD;
Seizures&#xD;
Drowsy&#xD;
Hair loss&#xD;
Itching&#xD;
Weakness&#xD;
Bladder&#xD;
Future Uncertainty&#xD;
Visual Disorder&#xD;
Motor Dysfunction&#xD;
Communication Deficit&#xD;
Headaches Seizures Drowsy Hair loss Itching Weakness Bladder Future Uncertainty Scale Visual Disorder Scale Motor Dysfunction Scale Communication Deficit Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Participants With Hippocampus Brain Metastases Following Sparing PCI</measure>
    <time_frame>12 months</time_frame>
    <description>The number of participants with brain metastases after sparing PCI treatment was assessed to be compared to two existing studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess if Development of Leptomeningeal Carcinomatosis Following Sparing PCI is Higher Than Expected</measure>
    <time_frame>6 months, 12 months, 18 months and 24 months post radiation treatment</time_frame>
    <description>Determine whether development of leptomeningeal carcinomatosis following hippocampal-sparing PCI is higher than expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Surviving Following Hippocampal-sparing PCI</measure>
    <time_frame>Up to 24 months post radiation treatment</time_frame>
    <description>To evaluate the survival rates of study participants following hippocampal-sparing PCI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <condition>SCLC</condition>
  <condition>Small Cell Lung Cancer Limited Stage</condition>
  <arm_group>
    <arm_group_label>Hippocampal-sparing PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hippocampal-sparing PCI 25 Gy in 10 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hippocampal-sparing Prophylactic Cranial Irradiation</intervention_name>
    <description>Hippocampal-sparing Prophylactic Cranial Irradiation</description>
    <arm_group_label>Hippocampal-sparing PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have newly diagnosed and confirmed small-cell lung cancer (SCLC)&#xD;
&#xD;
          -  Patient must have a performance status of 1 or higher&#xD;
&#xD;
          -  Patients must not have received previous irradiation to the brain&#xD;
&#xD;
          -  Patients must have limited stage disease with complete response to chemotherapy and&#xD;
             consolidative chest radiotherapy that was documented at least on standard chest x-rays&#xD;
             within one month of study entry&#xD;
&#xD;
          -  Negative MRI or CT scan of the brain at least one month before protocol entry&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test and also agree to&#xD;
             use adequate contraceptives while on protocol&#xD;
&#xD;
          -  Patient must be able to understand and sign the informed consent document&#xD;
&#xD;
          -  Patient must be informed of the investigational aspect to this trial prior to singing&#xD;
             the informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving prior external beam irradiation to the head or neck, including any&#xD;
             form of stereotactic irradiation&#xD;
&#xD;
          -  Radiographic evidence of brain metastases and/or ipsilateral lung metastases/malignant&#xD;
             pleural effusion&#xD;
&#xD;
          -  Planned concurrent chemotherapy or antitumoral agent during PCI&#xD;
&#xD;
          -  Concomitant malignancy or malignancy within the past five years other than&#xD;
             nonmelanomatous skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Patients with minimal pleural effusion evident on chest X-ray; minimal pleural&#xD;
             effusion visible on chest CT is allowed.&#xD;
&#xD;
          -  Patients with epilepsy requiring permanent oral medication&#xD;
&#xD;
          -  Patients must not have a serious medical or psychiatric illness that would, in the&#xD;
             opinion of the investigator, prevent informed consent or completion of protocol&#xD;
             treatment, and/or follow-up visits.&#xD;
&#xD;
          -  Patients may not take Memantine. This is the only eligibility criterion that has been&#xD;
             added to those of RTOG 0212, since some physicians might now prescribe Memantine. This&#xD;
             medication would not have been given at the time of enrollment on RTOG 0212 and its&#xD;
             administration could confound the results of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Redmond, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <results_first_submitted>June 3, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylactic Cranial Irradiation</keyword>
  <keyword>PCI</keyword>
  <keyword>Hippocampal-sparing irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share data with PIs who are not included on the study team.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT01797159/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hippocampal-sparing PCI</title>
          <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hippocampal-sparing PCI</title>
          <description>Hippocampal-sparing PCI 25 Gy in 10 fractions&#xD;
Hippocampal-sparing Prophylactic Cranial Irradiation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="38" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) on Possible Delayed Recall Toxicity as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R) for Delayed Recall</title>
        <description>The primary endpoint of this study is cognitive function or memory. Memory is measured by participant performance on the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-Delayed Recall) at 6 months following hippocampal-sparing PCI. The HVLT-Delayed minimum and Maximum scores are 0-12. A higher score means a better outcome.</description>
        <time_frame>Baseline, 6 months and 12 months post radiation treatment</time_frame>
        <population>At the 6 month timepoint, only 17 participants completed the test, and at the 12 month time point only 14 participants took the test.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing PCI 25 Gy in 10 fractions&#xD;
Hippocampal-sparing Prophylactic Cranial Irradiation: Hippocampal-sparing Prophylactic Cranial Irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) on Possible Delayed Recall Toxicity as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R) for Delayed Recall</title>
          <description>The primary endpoint of this study is cognitive function or memory. Memory is measured by participant performance on the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-Delayed Recall) at 6 months following hippocampal-sparing PCI. The HVLT-Delayed minimum and Maximum scores are 0-12. A higher score means a better outcome.</description>
          <population>At the 6 month timepoint, only 17 participants completed the test, and at the 12 month time point only 14 participants took the test.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</title>
        <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
        <time_frame>Baseline</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). 19 participants completed the test at baseline. No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing PCI 25 Gy in 10 fractions&#xD;
Hippocampal-sparing Prophylactic Cranial Irradiation: Hippocampal-sparing Prophylactic Cranial Irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</title>
          <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). 19 participants completed the test at baseline. No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HVLT-R Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT-R Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT-R Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COWA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BTA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Letter Word Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Category Word Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Verbal Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" spread=".562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and Memory: Verbal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and Memory: Visual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</title>
        <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
        <time_frame>6 months post radiation treatment</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). 14 participants completed the test at 6 months. No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing PCI 25 Gy in 10 fractions&#xD;
Hippocampal-sparing Prophylactic Cranial Irradiation: Hippocampal-sparing Prophylactic Cranial Irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</title>
          <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). 14 participants completed the test at 6 months. No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HVLT-R Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT-R Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT-R Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COWA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BTA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Letter Word Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Category Word Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Verbal Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.64" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and Memory: Verbal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and Memory: Visual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</title>
        <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
        <time_frame>12 months post radiation treatment</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). 14 participants completed the test at 12 months. No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing PCI 25 Gy in 10 fractions&#xD;
Hippocampal-sparing Prophylactic Cranial Irradiation: Hippocampal-sparing Prophylactic Cranial Irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Cognitive Function Following Sparing PCI to That of Standard PCI</title>
          <description>Composite cognitive function following hippocampal-sparing PCI relative to a historical control receiving standard PCI.&#xD;
HVLT-R Hopkins Verbal Learning Test Revised and Brief Visuospatial Memory Test-Revised (BVMT-R)&#xD;
Total Recall (0-36) higher = better&#xD;
Delayed Recall (0-12) higher = better&#xD;
Discrimination (-12 to 12) higher = better Trail Making A &amp; B (0-300 seconds) higher = poorer Controlled Oral Word Association (COWA) (0-180) higher = better Mini-Mental State Exam (MMSE) (0-30) higher = better Perceptual Comparison Test (PCT) (0-128) higher = better Brief Test of Attention (BTA) (0-20) higher = better Calibrated Ideational Fluency Assessment (CIFA)&#xD;
Letter Word Fluency (0-120) higher = better&#xD;
Category Word Fluency (0-120) higher = better&#xD;
Verbal Fluency (0-240) higher = better Learning and Memory&#xD;
Verbal Composite T score (mean = 100, standard deviation = 15), higher = better&#xD;
Visual Composite T score (mean = 100, standard deviation = 15), higher = better</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). 14 participants completed the test at 12 months. No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HVLT-R Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT-R Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HVLT-R Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trail Making B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.2" spread="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COWA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMSE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BTA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Letter Word Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Category Word Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIFA: Verbal Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BVMT-R Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and Memory: Verbal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and Memory: Visual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire (QLQ)-C30</title>
        <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from &quot;not at all&quot; to &quot;very much&quot;. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following:&#xD;
Dyspnoea&#xD;
Insomnia&#xD;
Appetite&#xD;
Constipation&#xD;
Diarrhoea&#xD;
Finances&#xD;
Fatigue&#xD;
Nausea/Vomiting&#xD;
Pain&#xD;
Physical Function&#xD;
Role Function&#xD;
Emotional Function&#xD;
Cognitive Function&#xD;
Social Function&#xD;
Global QoL</description>
        <time_frame>Baseline and 6 months post radiation treatment</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire (QLQ)-C30</title>
          <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from &quot;not at all&quot; to &quot;very much&quot;. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following:&#xD;
Dyspnoea&#xD;
Insomnia&#xD;
Appetite&#xD;
Constipation&#xD;
Diarrhoea&#xD;
Finances&#xD;
Fatigue&#xD;
Nausea/Vomiting&#xD;
Pain&#xD;
Physical Function&#xD;
Role Function&#xD;
Emotional Function&#xD;
Cognitive Function&#xD;
Social Function&#xD;
Global QoL</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global QoL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment QLQ-C30</title>
        <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from &quot;not at all&quot; to &quot;very much&quot;. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following:&#xD;
Dyspnoea&#xD;
Insomnia&#xD;
Appetite&#xD;
Constipation&#xD;
Diarrhoea&#xD;
Finances&#xD;
Fatigue&#xD;
Nausea/Vomiting&#xD;
Pain&#xD;
Physical Function&#xD;
Role Function&#xD;
Emotional Function&#xD;
Cognitive Function&#xD;
Social Function&#xD;
Global QoL</description>
        <time_frame>Baseline and 12 months post radiation treatment</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment QLQ-C30</title>
          <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire (QLQ-C30) assessment are on a four-point scale from &quot;not at all&quot; to &quot;very much&quot;. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Questions on the QLQ-C30 cover the following:&#xD;
Dyspnoea&#xD;
Insomnia&#xD;
Appetite&#xD;
Constipation&#xD;
Diarrhoea&#xD;
Finances&#xD;
Fatigue&#xD;
Nausea/Vomiting&#xD;
Pain&#xD;
Physical Function&#xD;
Role Function&#xD;
Emotional Function&#xD;
Cognitive Function&#xD;
Social Function&#xD;
Global QoL</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global QoL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire-Brain Cancer (QLQ-BN20)</title>
        <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following:&#xD;
Headaches&#xD;
Seizures&#xD;
Drowsy&#xD;
Hair loss&#xD;
Itching&#xD;
Weakness&#xD;
Bladder&#xD;
Future Uncertainty&#xD;
Visual Disorder&#xD;
Motor Dysfunction&#xD;
Communication Deficit</description>
        <time_frame>Baseline and 6 months post radiation treatment</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Quality of Life Questionnaire-Brain Cancer (QLQ-BN20)</title>
          <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 6 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following:&#xD;
Headaches&#xD;
Seizures&#xD;
Drowsy&#xD;
Hair loss&#xD;
Itching&#xD;
Weakness&#xD;
Bladder&#xD;
Future Uncertainty&#xD;
Visual Disorder&#xD;
Motor Dysfunction&#xD;
Communication Deficit</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headaches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hair loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future Uncertainty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication Deficit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Using the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20).</title>
        <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following:&#xD;
Headaches&#xD;
Seizures&#xD;
Drowsy&#xD;
Hair loss&#xD;
Itching&#xD;
Weakness&#xD;
Bladder&#xD;
Future Uncertainty&#xD;
Visual Disorder&#xD;
Motor Dysfunction&#xD;
Communication Deficit&#xD;
Headaches Seizures Drowsy Hair loss Itching Weakness Bladder Future Uncertainty Scale Visual Disorder Scale Motor Dysfunction Scale Communication Deficit Scale</description>
        <time_frame>Baseline and 12 months post radiation treatment</time_frame>
        <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Change in Quality of Life of Hippocampal-sparing PCI Treatment Outcome to Standard PCI Treatment Using the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20).</title>
          <description>Evaluate quality of life following hippocampal-sparing PCI relative to historical control receiving standard PCI. Difference between 12 months and baseline.&#xD;
Questions on the Quality of Life Questionnaire-Brain Cancer (QLQ-BN20) are rated on a four-point scale ('not at all', 'a little', 'quite a bit' and 'very much'), and are linearly transformed to a 0-100 scale. Higher scores represent more severe symptoms. Questions on the QLQ-BN20 cover the following:&#xD;
Headaches&#xD;
Seizures&#xD;
Drowsy&#xD;
Hair loss&#xD;
Itching&#xD;
Weakness&#xD;
Bladder&#xD;
Future Uncertainty&#xD;
Visual Disorder&#xD;
Motor Dysfunction&#xD;
Communication Deficit&#xD;
Headaches Seizures Drowsy Hair loss Itching Weakness Bladder Future Uncertainty Scale Visual Disorder Scale Motor Dysfunction Scale Communication Deficit Scale</description>
          <population>Data is presented for Hippocampal-sparing PCI (from this study). No data from standard PCI for comparison to be done.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headaches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hair loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future Uncertainty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Communication Deficit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Participants With Hippocampus Brain Metastases Following Sparing PCI</title>
        <description>The number of participants with brain metastases after sparing PCI treatment was assessed to be compared to two existing studies.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants With Hippocampus Brain Metastases Following Sparing PCI</title>
          <description>The number of participants with brain metastases after sparing PCI treatment was assessed to be compared to two existing studies.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess if Development of Leptomeningeal Carcinomatosis Following Sparing PCI is Higher Than Expected</title>
        <description>Determine whether development of leptomeningeal carcinomatosis following hippocampal-sparing PCI is higher than expected.</description>
        <time_frame>6 months, 12 months, 18 months and 24 months post radiation treatment</time_frame>
        <population>Data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Assess if Development of Leptomeningeal Carcinomatosis Following Sparing PCI is Higher Than Expected</title>
          <description>Determine whether development of leptomeningeal carcinomatosis following hippocampal-sparing PCI is higher than expected.</description>
          <population>Data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Surviving Following Hippocampal-sparing PCI</title>
        <description>To evaluate the survival rates of study participants following hippocampal-sparing PCI.</description>
        <time_frame>Up to 24 months post radiation treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hippocampal-sparing PCI</title>
            <description>Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) 25 Gy in 10 fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Surviving Following Hippocampal-sparing PCI</title>
          <description>To evaluate the survival rates of study participants following hippocampal-sparing PCI.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="68" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were followed for a one-year period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hippocampal-sparing PCI</title>
          <description>Hippocampal-sparing PCI 25 Gy in 10 fractions&#xD;
Hippocampal-sparing Prophylactic Cranial Irradiation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hearing Changes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Visual</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomit</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Memory Loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Taste Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheaded</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hot Flash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Personality Behavioral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dsypnea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharynx and esophogus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain due to radiation therapy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>The SKCCC at Johns Hopkins</name_or_title>
      <organization>The SKCCC at Johns Hopkins</organization>
      <phone>4109556980</phone>
      <email>kjansen3@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

